These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 20615303)

  • 1. Is there adequate provision of venous thromboembolism prophylaxis following hip arthroplasty? An audit and international survey.
    Rogers BA; Phillips S; Foote J; Drabu KJ
    Ann R Coll Surg Engl; 2010 Nov; 92(8):668-72. PubMed ID: 20615303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of thromboprophylaxis with low-molecular-weight heparin or rivaroxaban in hip and knee replacement surgery: findings from the ORTHO-TEP registry.
    Beyer-Westendorf J; Lützner J; Donath L; Tittl L; Knoth H; Radke OC; Kuhlisch E; Stange T; Hartmann A; Günther KP; Weiss N; Werth S
    Thromb Haemost; 2013 Jan; 109(1):154-63. PubMed ID: 23197272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elective hip and knee arthroplasty and the effect of rivaroxaban and enoxaparin thromboprophylaxis on wound healing.
    Sindali K; Rose B; Soueid H; Jeer P; Saran D; Shrivastava R
    Eur J Orthop Surg Traumatol; 2013 May; 23(4):481-6. PubMed ID: 23412293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rivaroxaban vs. low molecular weight heparin for the prevention of venous thromboembolism after hip or knee arthroplasty: a cohort study.
    Lazo-Langner A; Fleet JL; McArthur E; Garg AX
    J Thromb Haemost; 2014 Oct; 12(10):1626-35. PubMed ID: 25069387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Adherence to and satisfaction with oral outpatient thromboembolism prophylaxis compared to parenteral: SALTO study].
    Peidro-Garcés L; Otero-Fernandez R; Lozano-Lizarraga L
    Rev Esp Cir Ortop Traumatol; 2013; 57(1):53-60. PubMed ID: 23594983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of rivaroxaban versus low-molecular-weight heparin therapy in patients with lower limb fractures.
    Long A; Zhang L; Zhang Y; Jiang B; Mao Z; Li H; Zhang S; Xie Z; Tang P
    J Thromb Thrombolysis; 2014 Oct; 38(3):299-305. PubMed ID: 24402194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low molecular weight heparin versus other anti-thrombotic agents for prevention of venous thromboembolic events after total hip or total knee replacement surgery: a systematic review and meta-analysis.
    Lu X; Lin J
    BMC Musculoskelet Disord; 2018 Sep; 19(1):322. PubMed ID: 30193575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rivaroxaban: an oral factor Xa inhibitor.
    Thomas TF; Ganetsky V; Spinler SA
    Clin Ther; 2013 Jan; 35(1):4-27. PubMed ID: 23328267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mobile Compression Reduces Bleeding-related Readmissions and Wound Complications After THA and TKA.
    Arsoy D; Giori NJ; Woolson ST
    Clin Orthop Relat Res; 2018 Feb; 476(2):381-387. PubMed ID: 29529673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utilization Patterns, Efficacy, and Complications of Venous Thromboembolism Prophylaxis Strategies in Primary Hip and Knee Arthroplasty as Reported by American Board of Orthopedic Surgery Part II Candidates.
    Runner RP; Gottschalk MB; Staley CA; Pour AE; Roberson JR
    J Arthroplasty; 2019 Apr; 34(4):729-734. PubMed ID: 30685257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of complications requiring return to theatre in hip and knee arthroplasty patients taking enoxaparin versus rivaroxaban for thromboprophylaxis.
    Chahal GS; Saithna A; Brewster M; Gilbody J; Lever S; Khan WS; Foguet P
    Ortop Traumatol Rehabil; 2013; 15(2):125-9. PubMed ID: 23652532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of oral factor Xa inhibitor and low-molecular-weight heparin on surgical complications following total hip arthroplasty.
    Kim SM; Moon YW; Lim SJ; Kim DW; Park YS
    Thromb Haemost; 2016 Mar; 115(3):600-7. PubMed ID: 26790579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials.
    Huisman MV; Quinlan DJ; Dahl OE; Schulman S
    Circ Cardiovasc Qual Outcomes; 2010 Nov; 3(6):652-60. PubMed ID: 20923996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer's perspective.
    Duran A; Sengupta N; Diamantopoulos A; Forster F; Kwong L; Lees M
    J Med Econ; 2011; 14(6):824-34. PubMed ID: 22023098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of rivaroxaban for short- and long-term treatment of venous thromboembolism.
    Cohen AT; Dobromirski M
    Thromb Haemost; 2012 Jun; 107(6):1035-43. PubMed ID: 22371186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rivaroxaban: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery.
    Duggan ST; Scott LJ; Plosker GL
    Drugs; 2009; 69(13):1829-51. PubMed ID: 19719335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale and design of XAMOS: noninterventional study of rivaroxaban for prophylaxis of venous thromboembolism after major hip and knee surgery.
    Turpie AG; Schmidt AC; Kreutz R; Lassen MR; Jamal W; Mantovani L; Haas S
    Vasc Health Risk Manag; 2012; 8():363-70. PubMed ID: 22701330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rivaroxaban and dabigatran etexilate: two new oral anticoagulants for extended postoperative prevention of venous thromboembolism after elective total hip arthroplasty.
    Borris LC
    Arch Orthop Trauma Surg; 2010 May; 130(5):583-9. PubMed ID: 19565250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial.
    Kakkar AK; Brenner B; Dahl OE; Eriksson BI; Mouret P; Muntz J; Soglian AG; Pap AF; Misselwitz F; Haas S;
    Lancet; 2008 Jul; 372(9632):31-9. PubMed ID: 18582928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rivaroxaban: a review of its use for the prophylaxis of venous thromboembolism after total hip or knee replacement surgery.
    Duggan ST
    Am J Cardiovasc Drugs; 2012 Feb; 12(1):57-72. PubMed ID: 22272729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.